Find Funding Opportunities

National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to invite exploratory and innovative researchapplications focused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this FOA. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in the first quarter of 2023 with an expected application due date in late Spring 2023. This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to invite exploratory and innovative researchapplications focused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this FOA. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in the first quarter of 2023 with an expected application due date in late Spring 2023. This FOA will utilize the R21 activity code. Details of the planned FOA are provided below.

This NINDS Notice provides additional guidance for requesting funded extensions for NINDS K award recipients impacted by COVID-19.

Correcting total vs direct cost in the text.

The COVID-19 pandemic continues to be the source of much mortality and morbidity creating and contributing to both physical and mental health issues. Recent data suggest that over 825,000 individuals have died from COVID-19 in the United States including over 8600 deaths in the week ending January 5, 2022.However, the impact of the SARS-CoV-2 virus as well as the associated measures to prevent and treat this infection extend well beyond the issue of mortality. Although much needed information regarding the epidemiology, transmission and potential acute treatments including the development of an effective vaccine have been gleaned in unprecedented time, important issues remain to be elucidated including, but not limited to the effect of the virus and its therapy on menstrual health, fertility and the offspring of infected and/or vaccinated parents, the impact of the relatively recent Delta and Omicron variants and other emerging variants, the occurrence of viral co-infections and the many physical and mental health issues created by the pandemic itself.

The purpose of this funding opportunity is to provide an avenue for researchers to pursue funding to conduct research addressing these emerging and existing COVID-related issues. The goal of this NOSI is to not replace or compete with the various COVID-related funding opportunities currently available, but rather, to complement them by offering a funding opportunity to address key issues not currently covered by available COVID-related funding announcements among pregnant and lactating people, infants, children and adolescents in a most timely manner. Research projects addressing issues that are the focus of currently available or future COVID funding opportunity announcements will be encouraged to submit to those announcements. Also, the sharing of COVID related data and resources and effective communication of results are a high priority of the NIH. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches.

The NINDS F32 is designed specifically to support postdoctoral fellows who are beginning their training period in a new laboratory or research environment. Applicants are only eligible to apply for the NINDS F32 either before beginning or within the first 12 months of joining the postdoctoral lab in which the fellowship will be active. Given this eligibility window, many applicants apply either before or within the first 3 months in the laboratory (~30% of applicants have been in the postdoctoral laboratory for less than 3 months). At the start of the COVID-19 pandemic many laboratories across the country shut down. This would have been particularly detrimental to those transitioning to their new positions, which in most cases required not only a change in research institution but a move to a different city and/or state. Clearly, for those starting a new postdoctoral position right as the pandemic hit, labs began to close down amid uncertainty and remote interactions were just beginning to be developed. Although pandemic-related delays were not unique to a specific cohort of trainees, the individuals who were just starting in new postdoctoral positions during the initial months of the pandemic were some of the hardest hit in terms of their ability to integrate into and begin research-related activities in new laboratories. Consequently, NINDS will provide a 1-receipt cycle extension of eligibility to individuals who started in their new laboratory between February 1 and May 30 of 2020. Ordinarily, the last NINDS F32 due date for these individuals would have been February, 2021. With this extension, these individuals will now be eligible to apply for the June, 2021 due date.

The purpose of this Request for Information (RFI) is to solicit public comment on the use of Common Data Elements (CDEs) in NIH-funded research, particularly in the context of research on COVID-19.

The purpose of this Notice is to inform the extramural community that as a result of disruptions caused by the COVID-19 pandemic, the BRAIN Initiative will be providing up to a two-receipt cycle extension (roughly eight additional months) of eligibility for prospective applicants meeting the requirements for submission of an application to the BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) through the February/March 2021 due dates.

Notice Change: Late Application Policy September 28, 2020, Application Due Date RFA-NS-21-001 NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)" Notice Number: NOT-NS-20-097 Key Dates Release Date: August 11, 2020 Related Announcements RFA-NS-21-001 - NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform applicants a change the late application policy the September 28, 2020, Application Due Date RFA-NS-21-001 "NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)". NINDS understands the public health emergency related the Coronavirus Disease 2019) adversely affect applicants' ability submit applications a timely manner.  Late applications be accepted through 5:00 PM local time October 13, 2020, RFA-NS-21-001 "NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)".  late applications submitted after October 13, 2020 be considered. cover letter citing Notice NOT-NS-20-097) be submitted, it not required. the September 28, 2021, September 28, 2022, application due date(s), NIH Policy Late Submission Grant Applications NOT-OD-15-039 applies. RFA modified no longer state, "No late applications be accepted this Funding Opportunity Announcement."  Application Due Date(s) September 28, 2020, September 28, 2021, September 28, 2022 applications due 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Application Due Date(s) September 28, 2020, September 28, 2021, September 28, 2022 applications due 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: Beth-Anne.Sieber@nih.gov